PharmaEngine, Inc. (TPEX:4162)
Taiwan
· Delayed Price · Currency is TWD 55.10
+1.30 (2.42%)
Apr 28, 2026, 1:30 PM CST
PharmaEngine Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 911.42 | 2,523 | 767.67 | 654.38 | 654.84 | Upgrade
|
| Revenue Growth (YoY) | -63.88% | 228.70% | 17.31% | -0.07% | -37.99% | Upgrade
|
| Cost of Revenue | 51.85 | 47.74 | 48.7 | 49.7 | 37.07 | Upgrade
|
| Gross Profit | 859.56 | 2,476 | 718.97 | 604.68 | 617.76 | Upgrade
|
| Selling, General & Admin | 134.37 | 155.37 | 131.51 | 140.06 | 118.4 | Upgrade
|
| Research & Development | 299.72 | 267.03 | 310.28 | 181.88 | 136.89 | Upgrade
|
| Operating Expenses | 434.1 | 422.4 | 441.79 | 321.95 | 255.07 | Upgrade
|
| Operating Income | 425.46 | 2,053 | 277.18 | 282.74 | 362.69 | Upgrade
|
| Interest Expense | -0.14 | -0.18 | -0.31 | -0.08 | -0.21 | Upgrade
|
| Interest & Investment Income | 96.1 | 72.14 | 54.32 | 25.57 | 15.42 | Upgrade
|
| Currency Exchange Gain (Loss) | -12.24 | 37.66 | -2.13 | 8.8 | -15.68 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.11 | 0.21 | - | 0.03 | 0.31 | Upgrade
|
| EBT Excluding Unusual Items | 509.29 | 2,163 | 329.06 | 317.06 | 362.53 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 5.53 | 45.46 | 0.82 | Upgrade
|
| Other Unusual Items | - | - | 3.39 | 29.95 | 182.04 | Upgrade
|
| Pretax Income | 509.29 | 2,163 | 337.97 | 392.47 | 545.4 | Upgrade
|
| Income Tax Expense | 121.65 | 411.97 | 63.32 | 73.68 | 119.36 | Upgrade
|
| Net Income | 387.64 | 1,751 | 274.65 | 318.78 | 426.03 | Upgrade
|
| Net Income to Common | 387.64 | 1,751 | 274.65 | 318.78 | 426.03 | Upgrade
|
| Net Income Growth | -77.86% | 537.55% | -13.84% | -25.17% | -29.50% | Upgrade
|
| Shares Outstanding (Basic) | 144 | 144 | 144 | 144 | 145 | Upgrade
|
| Shares Outstanding (Diluted) | 144 | 144 | 144 | 144 | 145 | Upgrade
|
| Shares Change (YoY) | 0.01% | 0.13% | 0.03% | -0.72% | -0.80% | Upgrade
|
| EPS (Basic) | 2.70 | 12.19 | 1.91 | 2.22 | 2.95 | Upgrade
|
| EPS (Diluted) | 2.69 | 12.17 | 1.91 | 2.22 | 2.94 | Upgrade
|
| EPS Growth | -77.90% | 537.17% | -13.96% | -24.49% | -28.99% | Upgrade
|
| Free Cash Flow | 1,727 | 455.92 | 256.56 | 198.57 | 929.44 | Upgrade
|
| Free Cash Flow Per Share | 11.99 | 3.17 | 1.78 | 1.38 | 6.42 | Upgrade
|
| Dividend Per Share | 2.000 | 6.000 | 1.500 | 2.000 | 2.700 | Upgrade
|
| Dividend Growth | -66.67% | 300.00% | -25.00% | -25.93% | 8.00% | Upgrade
|
| Gross Margin | 94.31% | 98.11% | 93.66% | 92.41% | 94.34% | Upgrade
|
| Operating Margin | 46.68% | 81.37% | 36.11% | 43.21% | 55.39% | Upgrade
|
| Profit Margin | 42.53% | 69.39% | 35.78% | 48.72% | 65.06% | Upgrade
|
| Free Cash Flow Margin | 189.44% | 18.07% | 33.42% | 30.34% | 141.94% | Upgrade
|
| EBITDA | 427.21 | 2,055 | 278.55 | 283.44 | 363.39 | Upgrade
|
| EBITDA Margin | 46.87% | 81.43% | 36.29% | 43.31% | 55.49% | Upgrade
|
| D&A For EBITDA | 1.75 | 1.65 | 1.37 | 0.71 | 0.7 | Upgrade
|
| EBIT | 425.46 | 2,053 | 277.18 | 282.74 | 362.69 | Upgrade
|
| EBIT Margin | 46.68% | 81.37% | 36.11% | 43.21% | 55.39% | Upgrade
|
| Effective Tax Rate | 23.89% | 19.05% | 18.74% | 18.77% | 21.89% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.